Milan, Italy – July 11, 2014 – Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, today announces that according to SIX Swiss Exchange’s notification, Newron’s shares will be included in the SXI Life Sciences and the SXI Bio+Medtech indices effective as of September 22, 2014, due to adjustments on the occasion of the ordinary index review.
The SXI Indices Family comprises industry sectors that are of particular significance to the Swiss economy; SXI stands for SIX Special Industry. The SXI sector index family was launched in 2004 with the purpose to increase the liquidity of shares listed on SIX Swiss Exchange that belong to internationally significant industries.
The SXI Life Sciences and SXI Bio+Medtech indices reflect the life sciences industry, one of Switzerland’s most prominent sectors. The weighting of each individual stock is capped at 10%, giving small and medium-sized companies a greater impact. For more detail, please see http://www.six-swiss-exchange.com/indices/data_centre/shares/sxi_life_de.html and http://www.six-swiss-exchange.com/indices/data_centre/shares/sxi_biom_de.html.
Stefan Weber, Newron’s CEO, commented: “We are proud to be included in these indices, soon, and expect this to further broaden our shareholder base and provide additional liquidity for our shares going forward.”
About Newron Pharmaceuticals
Newron (SIX: NWRN) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the Central Nervous System (CNS) and pain. The Company is headquartered in Bresso near Milan, Italy. Following the submission of the Marketing Authorization Application (MAA) for safinamide for the treatment of Parkinson’s disease to the European Medicines Agency (EMA) in December 2013, to Swissmedic in March, 2014 as well as the New Drug Application NDA to the US FDA, Newron is working towards global approval of the compound, together with its partners. Zambon Group has the rights to commercialize safinamide globally, excluding Japan and other key Asian territories where Meiji Seika has the rights to develop and commercialize the compound. Newron’s additional projects are based on highly promising treatments for rare disease patients and are at various stages of clinical development, including sarizotan for patients with Rett syndrome, sNN0031 for patients with Parkinson’s disease, non-responsive to oral drug treatments, sNN0029 for patients with ALS and ralfinamide for patients with specific rare pain indications. Newron is also developing NW-3509 as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia. www.newron.com
Media
Italy
Stefan Weber - CEO
Phone: +39 02 6103 46 26
E-mail: pr@newron.com
UK/Global media
Julia Phillips
FTI Consulting
Phone: +44 (0)20 3727 1000
Switzerland
Martin Meier-Pfister IRF Communications
Phone: +41 43 244 81 40
Investors and analysts
Stefan Weber - CEO
Phone: +39 02 6103 46 30
E-mail: ir@newron.com
Help employers find you! Check out all the jobs and post your resume.
